Ongoing uncertainty about prices will deter new drug launches in Canada

Further delays in access or complete denials of access to innovative drugs will hurt even more Canadians with unmet or poorly met health needs that could be helped by these medicines.

Health Minister Jean-Yves Duclos speaks at an Aug. 23 press conference in Ottawa. Canada’s attractiveness as a marketplace for new medicines has already diminished as a result of uncertainty about the PMPRB changes, write Nigel Rawson and Brett Skinner. The Hill Times photograph by Andrew Meade

Opinion

BY NIGEL RAWSON AND BRETT SKINNER

September 7, 2022

In April, the federal minister of health announced that the government would not proceed with two of thr...

To keep reading, subscribe and become a political insider.

Only $7.76 a week for an annual subscription.

Enjoy unlimited website access and the digital newspaper.

Cancel anytime.

Already a Subscriber?

Get Weekend Point of View Newsletter

A round up of the past weekâ€™s opinion writers and columnists on Saturdays and Sundays.

By entering your email address you consent to receive email from The Hill Times containing news, analysis, updates and offers. You may unsubscribe at any time. See our privacy policy